搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
14 天
HER2突变肺癌新希望!勃林格殷格翰创新肿瘤疗法Zongertinib效果显著
Beamion LUNG-1 Ib期研究达到了主要终点,研究数据显示,客观缓解率(ORR)为66.7%,这一结果由中央独立盲态审查(BICR)评估。[1] 在脑转移患者中也观察到初步疗效,颅内缓解率为33%,疾病控制率(DCR)达到74%。 Zongertinib 整体耐受性良好,主要为轻度且可控的治疗相关不良事件(TRAE),因毒性导致的停药率较低,仅为3%。 截至数据截止时,仍有三分之二的患者 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Left note, bail denied
Didn't authorize apology
1951 kidnap victim found
NY reports death from EEE
Returning Indian antiquities
Texas sues Biden admin
1/3 think they have CTE
Seeks NIL compensation
Astronauts return to Earth
Makes emergency landing
No govt. shutdown for now
Closing last full-size store
Tech ban proposed
John becomes Category 3
Colo. shooter found guilty
Visits US ammunition plant
Reds fire manager
Co-founder testifies
Bulls escape MA rodeo
SpaceX plans Mars missions
Economic speech this week
Asks to be put on NY ballot
Friedkin set to buy Everton
FBI: Violent crime declined
More troops to Middle East
Gulf Coast storm warning
NE electoral change blocked
California sues ExxonMobil
反馈